Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.61 |
| ▸ | BRD2 | P25440 | 6/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.57 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12487 | 0.81 | NPC1 (0.69) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL5714196 | 0.81 | BRD4 (0.57) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL16404612 | 0.78 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL16246450 | 0.78 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL980536 | 0.78 | MAP4K4 (0.76) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL9657290 | 0.78 | BRD4 (0.62) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL19754248 | 0.78 | BRD4 (0.67) | BRD4BRD2CREBBPBRD3NPC1 | |
| Hydrochloric Acid SCHEMBL1016039 | 0.77 | MAP4K4 (0.73) | BRD4BRD2CREBBPBRD3NPC1 | |
| SCHEMBL19754238 | 0.76 | BRD4 (0.65) | BRD4BRD2CREBBPBRD3NPC1 | |
| 3,5-Dimethyl-4-Phenylisoxazole SCHEMBL12134072 | 0.76 | BRD4 (1.00) | BRD4BRD2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | claimed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| EP-1734961-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| WO-2005087714-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING BI-CYCLIC ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239832-A1 | Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors | APP, DNPEP, BACE1 | BRD4 1715/4885BRD2 2365/4885CREBBP 1328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.